Skip to main content

Table 1 Inclusion and exclusion criteria

From: Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial

Inclusion criteria Exclusion criteria
Age > 18 years
Reverse transcriptase–polymerase chain reaction -confirmed SARS–CoV-2 infection
Berlin criteria-defined acute respiratory distress syndrome for < 96 h
Respiratory support (invasive or non-invasive mechanical ventilation, and/or high-flow nasal oxygenation) with positive end-expiratory pressure equivalent ≥ 5 cm H2O
Age < 18 years
Acute respiratory distress syndrome present for > 96 h
Pulmonary fibrosis
Pulmonary hypertension (WHO classification class III or IV)
Pulmonary embolism within the previous 3 months
Extracorporeal membrane oxygenation or life support
Immunocompromised status including use of immunosuppressive medications
Pregnancy or breastfeeding
Treatment for cancer in the past 2 years
Underlying medical condition with life expectancy < 6 months
Moderate-to-severe liver disease (Child–Pugh score > 12)
Severe chronic lung disease with the use of home oxygen and/or partial arterial pressure of carbon dioxide > 50 mm Hg
Patients not committed to full support (i.e., had do not resuscitate or limit life support orders)
Participation in another trial of COVID-19 therapeutics